The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is a huge mover today! The stock increased 2.50% or $0.12 during the last trading session, reaching $4.92. About 1.45M shares traded or 21.20% up from the average. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has risen 75.08% since February 9, 2017 and is uptrending. It has outperformed by 58.38% the S&P500.The move comes after 8 months positive chart setup for the $484.29 million company. It was reported on Feb, 9 by Barchart.com. We have $5.36 PT which if reached, will make NASDAQ:BCRX worth $43.59 million more.
Morgan Stanley decreased American Intl Group Inc (AIG) stake by 5.92% reported in 2017Q3 SEC filing. Morgan Stanley sold 367,459 shares as American Intl Group Inc (AIG)’s stock declined 2.08%. The Morgan Stanley holds 5.84M shares with $358.38 million value, down from 6.21 million last quarter. American Intl Group Inc now has $53.70 billion valuation. The stock increased 2.49% or $1.45 during the last trading session, reaching $59.73. About 9.94 million shares traded or 83.77% up from the average. American International Group, Inc. (NYSE:AIG) has risen 8.59% since February 9, 2017 and is uptrending. It has underperformed by 8.11% the S&P500.
Morgan Stanley increased Handy & Harman Ltd (NASDAQ:HNH) stake by 14,246 shares to 17,996 valued at $586,000 in 2017Q3. It also upped Ascendis Pharma A S stake by 26,502 shares and now owns 67,332 shares. Range Res Corp (NYSE:RRC) was raised too.
Investors sentiment increased to 0.79 in 2017 Q3. Its up 0.15, from 0.64 in 2017Q2. It improved, as 72 investors sold AIG shares while 293 reduced holdings. 78 funds opened positions while 211 raised stakes. 748.00 million shares or 0.80% more from 742.03 million shares in 2017Q2 were reported. 1832 Asset Mgmt Ltd Partnership holds 0% of its portfolio in American International Group, Inc. (NYSE:AIG) for 5,578 shares. Quantitative Systematic Strategies Lc holds 0.32% or 19,400 shares. Chevy Chase Trust holds 857,022 shares. Invesco holds 10.27 million shares. Strs Ohio stated it has 673,499 shares. Murphy Capital Inc stated it has 69,868 shares or 0.61% of all its holdings. Bremer Tru Natl Association owns 10,663 shares. Moreover, Financial Engines Advsrs Limited Liability Corp has 0% invested in American International Group, Inc. (NYSE:AIG) for 793 shares. 96,603 were reported by Mayo Investment Advisers Ltd Co. Tarbox Family Office invested 0.01% of its portfolio in American International Group, Inc. (NYSE:AIG). Parallax Volatility Advisers LP reported 0% stake. Connor Clark & Lunn Investment Ltd holds 0.08% or 224,825 shares. State Of Alaska Department Of Revenue reported 22,532 shares or 0.07% of all its holdings. Gulf Int Bankshares (Uk) Ltd holds 290,784 shares or 0.24% of its portfolio. Shine Inv Advisory invested in 979 shares.
Among 21 analysts covering American International Group (NYSE:AIG), 13 have Buy rating, 2 Sell and 6 Hold. Therefore 62% are positive. American International Group had 72 analyst reports since August 5, 2015 according to SRatingsIntel. The company was upgraded on Friday, February 9 by Bank of America. The stock has “Market Perform” rating by FBR Capital on Friday, February 26. On Monday, August 22 the stock rating was maintained by BMO Capital Markets with “Market Perform”. As per Wednesday, November 4, the company rating was downgraded by Atlantic Securities. As per Wednesday, December 6, the company rating was upgraded by Deutsche Bank. Credit Suisse maintained the shares of AIG in report on Monday, January 22 with “Buy” rating. The stock has “Buy” rating by RBC Capital Markets on Monday, July 10. On Tuesday, March 29 the stock rating was maintained by Credit Suisse with “Neutral”. The stock has “Outperform” rating by RBC Capital Markets on Tuesday, February 16. The firm has “Hold” rating by Standpoint Research given on Monday, November 23.
Analysts await BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to report earnings on February, 26. They expect $-0.15 earnings per share, down 150.00% or $0.09 from last year’s $-0.06 per share. After $-0.18 actual earnings per share reported by BioCryst Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -16.67% EPS growth.
Among 14 analysts covering BioCryst Pharmaceuticals (NASDAQ:BCRX), 12 have Buy rating, 0 Sell and 2 Hold. Therefore 86% are positive. BioCryst Pharmaceuticals has $16 highest and $2 lowest target. $7.20’s average target is 46.34% above currents $4.92 stock price. BioCryst Pharmaceuticals had 34 analyst reports since August 7, 2015 according to SRatingsIntel. JP Morgan upgraded BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on Wednesday, September 6 to “Overweight” rating. Zacks upgraded BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on Friday, August 7 to “Sell” rating. The stock has “Hold” rating by Jefferies on Friday, August 5. H.C. Wainwright maintained BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) rating on Friday, May 26. H.C. Wainwright has “Buy” rating and $1000 target. JMP Securities maintained the stock with “Buy” rating in Tuesday, November 28 report. The firm has “Market Perform” rating by JMP Securities given on Thursday, August 4. The rating was upgraded by RBC Capital Markets to “Outperform” on Tuesday, January 2. The stock has “Buy” rating by Jefferies on Wednesday, September 6. The stock has “Buy” rating by H.C. Wainwright on Wednesday, November 8. The rating was upgraded by JMP Securities to “Market Outperform” on Friday, December 16.
Since September 18, 2017, it had 0 insider purchases, and 1 sale for $294,035 activity. Cohen Fred E sold $294,035 worth of stock.
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company has market cap of $484.29 million. The firm markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU. It currently has negative earnings. It also has various ongoing development programs, including BCX7353 and second generation oral inhibitors of plasma kallikrein for hereditary angioedema; and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is indicated to treat filoviruses, as well as forodesine, an oral purine nucleoside phosphorylase inhibitor for use in oncology.
Investors sentiment increased to 1.69 in 2017 Q3. Its up 0.01, from 1.68 in 2017Q2. It improved, as 12 investors sold BioCryst Pharmaceuticals, Inc. shares while 24 reduced holdings. 28 funds opened positions while 33 raised stakes. 79.80 million shares or 20.47% more from 66.24 million shares in 2017Q2 were reported. Comerica Natl Bank holds 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 16,421 shares. Laurion Capital Management L P stated it has 0.01% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Paloma Partners Mngmt accumulated 10,328 shares. 66,119 were reported by Aqr Capital Ltd Co. Planning Corp accumulated 32,000 shares. Citadel Advisors Limited Liability holds 0.01% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 1.40 million shares. Manufacturers Life Insur The reported 0% stake. Artal has 650,000 shares. Price T Rowe Assoc Inc Md stated it has 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Credit Suisse Ag owns 96,247 shares or 0% of their US portfolio. Acuta Capital Partners Limited Liability accumulated 996,300 shares. Oberweis Asset Mgmt invested in 0.03% or 17,100 shares. Pillar Pacific Capital Mgmt Ltd Liability Corporation has invested 0.01% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Franklin Street Advsr Nc holds 0.04% or 49,000 shares in its portfolio. Rock Springs Mngmt Limited Partnership reported 450,000 shares.